Date : 11/18/2009 @ 1:33PM
Source : MarketWire
Stock : IO News Wire (KKUR)
Quote : 0.0007 0.0003 (75.00%) @ 1:48PM
(PINKSHEETS: KKUR) on the Front Line of Cancer Detection
NEW YORK, NY -- (Marketwire) -- 11/18/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced recently its nationwide diagnostic lab partnership program to increase awareness of its CS200 Chromosomal Scanner, its leading cancer detection system.
ChromoCure's research demonstrates and confirms the 100% common chromosomal condition present in every form of cancer. By detecting this unique chromosomal condition the Company's ability to detect cancer, of all types and stages, is effectively 100% accurate. ChromoCure indicates they have the ability to completely eliminate false positives and false negatives for the presence of cancer.
ChromoCure believes its CS200 Chromosomal Scanner employs the fastest, most accurate method of detecting cancer in tissue samples by testing for cancer's unique chromosomal imbalance. The company's research and scientific literature both support this imbalance as the most accurate predictor of cancer available in today's market. The company does not believe any cancer technology exists that uses cancer's unique chromosomal condition combined with automated cell nucleus scanning.
ChromoCure is positioning itself in the $16.8 billion dollar cancer detection and therapy market by offering its CS200 Chromosomal Scanner and soon to be released CS300 Scanner free to all participating pathology labs along with training, materials and marketing guidance.
The Company also has certain initiatives underway to apply its understanding of cancer to both therapeutic technologies and possible cure.
Other active stocks are Biocentric Energy Holdings (PINKSHEETS: BEHL), Hologic (NASDAQ: HOLX), C.R. Bard, Inc. (NYSE: BCR).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send No Faxes or emails.
Contact:
Eric Jensen
www.ionewswire.com
516.942.4910
Source : MarketWire
Stock : IO News Wire (KKUR)
Quote : 0.0007 0.0003 (75.00%) @ 1:48PM
(PINKSHEETS: KKUR) on the Front Line of Cancer Detection
NEW YORK, NY -- (Marketwire) -- 11/18/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced recently its nationwide diagnostic lab partnership program to increase awareness of its CS200 Chromosomal Scanner, its leading cancer detection system.
ChromoCure's research demonstrates and confirms the 100% common chromosomal condition present in every form of cancer. By detecting this unique chromosomal condition the Company's ability to detect cancer, of all types and stages, is effectively 100% accurate. ChromoCure indicates they have the ability to completely eliminate false positives and false negatives for the presence of cancer.
ChromoCure believes its CS200 Chromosomal Scanner employs the fastest, most accurate method of detecting cancer in tissue samples by testing for cancer's unique chromosomal imbalance. The company's research and scientific literature both support this imbalance as the most accurate predictor of cancer available in today's market. The company does not believe any cancer technology exists that uses cancer's unique chromosomal condition combined with automated cell nucleus scanning.
ChromoCure is positioning itself in the $16.8 billion dollar cancer detection and therapy market by offering its CS200 Chromosomal Scanner and soon to be released CS300 Scanner free to all participating pathology labs along with training, materials and marketing guidance.
The Company also has certain initiatives underway to apply its understanding of cancer to both therapeutic technologies and possible cure.
Other active stocks are Biocentric Energy Holdings (PINKSHEETS: BEHL), Hologic (NASDAQ: HOLX), C.R. Bard, Inc. (NYSE: BCR).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send No Faxes or emails.
Contact:
Eric Jensen
www.ionewswire.com
516.942.4910